VIZZ
aceclidine ophthalmic solution · LNZ100- Presbyopia
LENZ Therapeutics
Most recent annual filing: 2026-03-24
Pipeline (1 active programs)
Discontinued (1)
- LNZ101 — Presbyopia · Dropped after Phase 3 CLARITY: LNZ101 (aceclidine + brimonidine) did not demonstrate superiority to LNZ100; company advances LNZ100 (VIZZ) exclusively.
Biotech Distilled coverage (1)
Articles open on Substack. Some deep dives are subscriber-only.